Scarica l'app Stockscreener
37.46
1.63%
0.60
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRNX Giù?
Forum
Previsione
Precedente Chiudi:
$36.86
Aprire:
$37.34
Volume 24 ore:
915.84K
Relative Volume:
1.14
Capitalizzazione di mercato:
$3.47B
Reddito:
$4.72M
Utile/perdita netta:
$-277.91M
Rapporto P/E:
-10.04
EPS:
-3.73
Flusso di cassa netto:
$-203.56M
1 W Prestazione:
+6.39%
1M Prestazione:
-3.35%
6M Prestazione:
-30.58%
1 anno Prestazione:
+2.91%
Intervallo 1D:
$36.70
$37.58
Intervallo di 1 settimana:
$35.10
$37.58
Portata 52W:
$34.07
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Nome
Crinetics Pharmaceuticals Inc
Settore
Industria
Telefono
858-450-6464
Indirizzo
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
Confronta CRNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
37.46 | 3.47B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Iniziato | TD Cowen | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Peer Perform |
| 2025-01-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-03-06 | Iniziato | Citigroup | Buy |
| 2024-01-16 | Iniziato | Morgan Stanley | Overweight |
| 2023-12-21 | Iniziato | Jefferies | Hold |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Iniziato | Oppenheimer | Outperform |
| 2023-04-24 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Robert W. Baird | Outperform |
| 2021-11-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-11-23 | Iniziato | Evercore ISI | Outperform |
| 2021-06-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Iniziato | ROTH Capital | Buy |
| 2019-02-14 | Iniziato | H.C. Wainwright | Buy |
| 2018-08-13 | Iniziato | JP Morgan | Neutral |
| 2018-08-13 | Iniziato | Leerink Partners | Outperform |
| 2018-08-13 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Crinetics Pharmaceuticals Inc Borsa (CRNX) Ultime notizie
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences - GlobeNewswire
Objective long/short (CRNX) Report - Stock Traders Daily
Crinetics Pharmaceuticals (CRNX) Expected to Announce Earnings on Wednesday - MarketBeat
TD Cowen initiates Crinetics stock with Buy rating, sees high potential - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 12-Month LowWhat's Next? - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Coverage Initiated at TD Cowen - MarketBeat
abrdn plc Acquires 7,922 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Research Coverage Started at TD Cowen - Defense World
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Janney Montgomery Scott LLC Purchases 600 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
TD Cowen gives a Buy recommendation for Crinetics Pharmaceuticals Inc (CRNX) - Knox Daily
CRNX stock touches 52-week low at $35.47 amid market shifts - MSN
Leerink Partnrs Issues Negative Estimate for CRNX Earnings - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 1-Year Low – Time to Sell? - Defense World
Stock Performance Spotlight: Crinetics Pharmaceuticals Inc (CRNX) Ends the Day at 36.53, Down by -1.22 - The Dwinnex
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Crinetics (CRNX) Awards $3.8M in Equity Incentives to Expand TeamKey Details - StockTitan
(CRNX) Technical Pivots with Risk Controls - Stock Traders Daily
Dana Pizzuti Sells 5,000 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock - MarketBeat
Calamos Advisors LLC Sells 27,156 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Coverage Initiated at Wolfe Research - MarketBeat
What is Leerink Partnrs’ Estimate for CRNX Q3 Earnings? - Defense World
Jennison Associates LLC Has $138.48 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - The Manila Times
Crinetics Q4 Earnings Date Confirmed: Key Financial Updates Expected Feb 27 - StockTitan
Crinetics Pharmaceuticals Inc (CRNX)’s Market Momentum: Closing Strong at 39.30, Down -2.72 - The Dwinnex
An analyst sees good growth prospects for Crinetics Pharmaceuticals Inc (CRNX) - SETE News
Wolfe Research Begins Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals exec sells shares worth $195,350 By Investing.com - Investing.com Nigeria
Crinetics Pharmaceuticals exec sells shares worth $195,350 - MSN
Crinetics Pharmaceuticals, Inc. (CRNX): One of January’s Biggest Losers - Insider Monkey
Keeping an Eye on Crinetics Pharmaceuticals Inc (CRNX) After Insider Trading Activity - Knox Daily
Wolfe Research Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Peer Perform Recommendation - MSN
KBC Group NV Grows Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals Inc Azioni (CRNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Crinetics Pharmaceuticals Inc Azioni (CRNX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pizzuti Dana | Chief Med and Dev Officer |
Feb 03 '25 |
Sale |
39.07 |
5,000 |
195,350 |
31,748 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):